1) Just making a point that sales will need to ramp up if GIA is the strategy.
No kidding. Might as well say they need to keep showing up for work. SMH!
2) I just hope this management is smart enough to recognize a good offer for where they are in the process. 800 sales reps for 1 drug is going to be an expensive rollout.
Disagree. The size of the market that I expect for Vascepa....the cost of 800 reps will be minuscule.
3) Why is it everyone on this board thinks they know everything (i.e. I haven't been in "biz") about everyone else? Where were you a CEO? Did you own the company? Did you sell it? Was it based on a multiple of EBITDA?
Because you say things that someone that knows nothing of business would say. I have owned 4 companies so far. All built by my wife and I. Started with nothing. Have enough that the future of almost 100k shares of amrn are not a huge concern. Its going to be nice but if it went to zero we would still be fine.
It’s not going to zero. It may go to a hundred. After watching some others I won’t be surprised if it does. For certain it’s going to turn a healthy profit in 2020 and if it stays independent it may make quite a bit more $$ than most think.
Market Data 
Markets 
AI
